论文部分内容阅读
目的观察多西紫杉醇联合吡柔比星在新辅助化疗治疗晚期乳腺癌的疗效及不良反应。方法 45例原发晚期乳腺癌患者采用多西紫杉醇联合吡柔比星方案,术前化疗2～4个周期,术后完成规定化疗,观察近期疗效及不良反应。结果新辅助化疗临床疗效总有效率为88%,其中3例病理为完全缓解,主要不良反应为呕吐,粒细胞减少及脱发。结论多西紫杉醇联合吡柔比星新辅助化疗治疗晚期乳腺癌疗效显著,不良反应可耐受,是新辅助化疗治疗晚期乳腺癌的有效方案之一。
Objective To observe the efficacy and adverse reactions of docetaxel and pirarubicin in the treatment of advanced breast cancer with neoadjuvant chemotherapy. Methods Forty-five patients with primary breast cancer were treated with docetaxel and pirarubicin. Preoperative chemotherapy was performed for 2 to 4 cycles. Chemotherapy was prescribed after operation to observe the short-term efficacy and adverse reactions. Results The total effective rate of neoadjuvant chemotherapy was 88%, of which 3 cases were completely relieved. The main adverse reactions were vomiting, neutropenia and alopecia. Conclusion Docetaxel combined with neoadjuvant chemotherapy of pirarubicin in the treatment of advanced breast cancer has obvious curative effect and tolerable side effects. It is one of the effective regimens of neoadjuvant chemotherapy for advanced breast cancer.